BiotechTube
Cambium Oncology

Cambium Oncology

Cambridge, United States· Est.
cambiumoncology.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Cambium Oncology is pioneering a novel class of immunotherapies targeting the VIP/VPAC axis, an immunosuppressive pathway exploited by cancer cells. Its lead candidate, CAMV-01, is a VIP antagonist designed to re-activate cytotoxic T-cells, with a pipeline that includes small molecules, cell therapies, and long-acting constructs. Founded on IP from Emory University and led by a seasoned team, the company employs a biomarker-driven, combination-focused strategy to de-risk development in a high-value oncology market. Cambium is a private, pre-revenue company advancing its programs through preclinical and early clinical development.

Oncology

Technology Platform

Platform focused on developing VIP (vasoactive intestinal peptide) antagonists that block the VIP/VPAC signaling axis, a novel neuroimmune checkpoint. The technology aims to restore immune surveillance by preventing cancer-cell-derived VIP from suppressing cytotoxic T-cell function.

Opportunities

The VIP pathway is a first-in-class, novel immuno-oncology target addressing a significant unmet need in patients resistant to current checkpoint inhibitors.
A biomarker-driven strategy (VIP/VPAC high tumors) could enable targeted clinical development with higher probability of success.
The platform's potential for combination with PD-1 inhibitors and its expansion into cell therapy (CAR-T) creates multiple shots on goal across different cancer modalities.

Risk Factors

The primary risk is clinical validation, as the VIP target is novel and unproven in humans, with potential safety concerns due to VIP's role in normal immune regulation.
The company faces significant financing risk as a pre-revenue entity requiring substantial capital for clinical trials.
It also operates in the highly competitive and crowded immuno-oncology space, where demonstrating differentiation is challenging.

Competitive Landscape

Cambium is a pioneer targeting the VIP/VPAC axis, with no approved therapies in this class, giving it potential first-mover advantage. However, it competes indirectly with all companies developing next-generation immunotherapies, including other novel checkpoint inhibitors, agonist antibodies, and combination regimens. Its success will depend on demonstrating superior efficacy or a unique patient population not addressed by existing therapies.

More companies in Immunotherapy / Immuno-Oncology →More companies in United States →